Upload
hoangnhan
View
215
Download
0
Embed Size (px)
Citation preview
High expression levels of bonemorphogenetic protein-2 and p-
glycoprotein related withprogressivity in patient with
osteosarcomaby I Ketut Suyasa
Submission date: 05-Sep-2018 09:16AM (UTC+0700)Submission ID: 996991118File name: tein_related_with_progressivity_in_patient_with_osteosarcoma.pdf (445.51K)Word count: 3218Character count: 17742
18%SIMILARITY INDEX
10%INTERNET SOURCES
14%PUBLICATIONS
6%STUDENT PAPERS
1 2%
2 2%
3 1%
4 1%
5 1%
6 1%
7 1%
High expression levels of bone morphogenetic protein-2 andp-glycoprotein related with progressivity in patient withosteosarcomaORIGINALITY REPORT
PRIMARY SOURCES
Submitted to Central Queensland UniversityStudent Paper
mdanderson.influuent.utsystem.eduInternet Source
Submitted to Clovis Community CollegeStudent Paper
mobile.repository.ubn.ru.nlInternet Source
Dsouza, Priya, and Maria Kuruville."Dyslipidemia in psoriasis: as a risk forcardiovascular disease", International Journalof Research in Medical Sciences, 2013.Publicat ion
www.ijbcp.comInternet Source
Ho, G-T. Moodie, F.M. Satsangi, J.. "Multidrugresistance 1 gene (P-glycoprotein 170): an
8 1%
9 1%
10 1%
11 1%
12 <1%
important determinant in gastrointestinaldisea", Gut, May 2003 IssuePublicat ion
Submitted to University of DerbyStudent Paper
Fujiwara, Tomohiro, Ryou-u Takahashi,Nobuyoshi Kosaka, Yutaka Nezu, Akira Kawai,Toshifumi Ozaki, and Takahiro Ochiya. "RPN2Gene Confers Osteosarcoma Cell MalignantPhenotypes and Determines ClinicalPrognosis", Molecular Therapy — NucleicAcids, 2014.Publicat ion
Liu, Xudong, Bingfang Zeng, Jie Ma, andChunling Wan. "Comparative ProteomicAnalysis of Osteosarcoma Cell and HumanPrimary Cultured Osteoblastic Cell", CancerInvestigation, 2009.Publicat ion
He, Hongtao, Jiangdong Ni, and Jun Huang."Molecular mechanisms of chemoresistance inosteosarcoma (Review)", Oncology Letters,2014.Publicat ion
mext-cancerinfo.tri-kobe.orgInternet Source
circres.ahajournals.org
13 <1%
14 <1%
15 <1%
16 <1%
17 <1%
18 <1%
19 <1%
Internet Source
www.thieme-connect.comInternet Source
Shen, F., B. J. Bailey, S. Chu, A. K. Bence, X.Xue, P. Erickson, A. R. Safa, W. T. Beck, and L.C. Erickson. "Dynamic Assessment ofMitoxantrone Resistance and Modulation ofMultidrug Resistance by Valspodar (PSC833) inMultidrug Resistance Human Cancer Cells",Journal of Pharmacology and ExperimentalTherapeutics, 2009.Publicat ion
Submitted to Seminole Community CollegeStudent Paper
hrcak.srce.hrInternet Source
Tang Liu, Zhihong Li, Qing Zhang, Karen DeAmorim Bernstein et al. "Targeting ABCB1(MDR1) in multi-drug resistant osteosarcomacells using the CRISPR-Cas9 system to reversedrug resistance", Oncotarget, 2016Publicat ion
Anja Luetke, Paul A. Meyers, Ian Lewis,Heribert Juergens. "Osteosarcoma treatment –Where do we stand? A state of the art review",
20 <1%
21 <1%
22 <1%
23 <1%
24 <1%
25 <1%
Cancer Treatment Reviews, 2014Publicat ion
www.everettclinic.comInternet Source
www.omicsonline.orgInternet Source
Haijun Tian, Jie Zhao, Elsa J. Brochmann,Jeffrey C. Wang, Samuel S. Murray. "Bonemorphogenetic protein-2 and tumor growth:Diverse effects and possibilities for therapy",Cytokine & Growth Factor Reviews, 2017Publicat ion
Stefano Ferrari. "Evaluation of P-glycoprotein,HER-2/ErbB-2, p53, and Bcl-2 in primary tumorand metachronous lung metastases in patientswith high-grade osteosarcoma", Cancer,05/01/2004Publicat ion
www.healio.comInternet Source
Li-Tzu Lee, Yong-Kie Wong, Man-Yee Chan,Kuo-Wei Chang, Shyh-Chang Chen, Chiou-TuzChang, John Wang. "The correlation betweenHIF-1 alpha and VEGF in oral squamous cellcarcinomas: Expression patterns andquantitative immunohistochemical analysis",
26 <1%
27 <1%
28 <1%
29 <1%
30 <1%
31 <1%
Journal of the Chinese Medical Association,2018Publicat ion
www.jsnm.orgInternet Source
Submitted to Pellissippi State TechnicalCommunity CollegeStudent Paper
Hattinger, Claudia Maria, Francesca Michelacci,Federica Sella, Giovanna Magagnoli, StefaniaBenini, Marco Gambarotti, EmanuelaPalmerini, Piero Picci, Massimo Serra, andStefano Ferrari. "ercc1 protein expressionpredicts survival in patients with high-grade,non-metastatic osteosarcoma treated withneoadjuvant chemotherapy", Histopathology,2015.Publicat ion
Cañadell s Pediatric Bone Sarcomas, 2016.Publicat ion
Jenny E Felin. "Nuclear variants of bonemorphogenetic proteins", BMC Cell Biology,2010Publicat ion
Gaetano Bacci. "Predictive factors for localrecurrence in osteosarcoma 540 patients withextremity tumors followed for minimum 2.5
32 <1%
Exclude quotes On
Exclude bibliography On
Exclude matches < 2 words
years after neoadjuvant chemotherapy", ActaOrthopaedica, 6/1/1998Publicat ion
Carragee, Eugene J.. "Cancer Risk After Use ofRecombinant Bone Morphogenetic Protein-2for Spinal Arthrodesis", The Journal of Boneand Joint Surgery (American), 2013.Publicat ion